- Details
- Zach Klaassen is joined by Karsten Zieger to talk about the results of an analysis from the Nordic registry evaluating the role of flexible blue light cystoscopy in the surveillance of non-muscle invasive bladder cancer. Dr. Zieger provides a comprehensive explanation of how blue light cystoscopy works. The method utilizes a photosensitizing agent, Hexvix in Europe or Cysview® in the U.S., that al...
|
- Details
- Leslie Ballas engages with Martin Swinton on his publication about bladder-sparing treatment options for clinically node-positive nonmetastatic bladder cancer. The study compares the efficacy of bladder-sparing treatment using radical dose radiotherapy to traditional radical cystectomy and finds no significant difference in overall survival rates. This supports bladder preservation as a viable alt...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ATLAS publication focusing on the treatment of low-grade intermediate-risk, non-muscle-invasive bladder cancer using UGN-102, with or without TURBT, in a phase III trial. The trial's main objective was to evaluate the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, versus traditional TURBT alone. Conducted across 72 sites in t...
|
- Details
- Ashish Kamat welcomes Charles Guo to discuss variant histology in bladder urothelial carcinoma, which constitutes about 90% of all bladder cancers. Dr. Guo meticulously explains the WHO classification into noninvasive and invasive types, detailing distinguishing features, aggressive behaviors, and distinct genomic alterations of various subtypes like micropapillary, plasmacytoid, and small cell ca...
|
- Details
- Sam Chang and Sarah Psutka discuss the importance of personalized prescriptions and rehabilitation in urologic oncology, with an emphasis on frailty evaluation and prehabilitation. Dr. Psutka urges the shift from subjective preoperative risk to objective measures for better treatment outcomes, using Comprehensive Geriatric Assessments (CGA) and anatomic assessments, while highlighting the correlat...
|
- Details
- Ashish Kamat and Wei Shen Tan delve into a discussion on the advances in device-assisted therapies for non-muscle-invasive bladder cancer. Dr. Tan details the history, mechanisms, and clinical trials of various therapies including chemohyperthermia and electromotive drug-administrated chemotherapy (EMDA). He also highlights newer treatments such as the TAR-200 system and Jelmyto. Despite promising...
|
- Details
- Ashish Kamat interviews Chris Garris, the 2023 Bladder Cancer Research Innovation Award recipient. Dr. Garris discusses his pioneering research project aimed at overcoming immune suppressive myeloid cell barriers in bladder cancer through immune agonism. He presents the CANDI therapeutic platform which uses IL-12-inducing drug combinations to stimulate immune responses for potentially more effecti...
|
- Details
- Andrew Hsieh highlights his team's research on a new tumor suppressor mechanism termed transcriptional-translational conflict. The research primarily focuses on ARID1A, a component of the SWI/SNF chromatin remodeling complex, which is frequently deregulated in bladder cancer. In absence of ARID1A, up-regulated oncogenic gene networks were observed, but no tumorigenesis occurred due to a conflict b...
|
- Details
- Zach Klaassen and Kevin Gallagher discuss the RESECT study. RESECT, a global research initiative across five continents and over 200 hospitals, aims to improve the quality of Transurethral Resection of Bladder Tumor (TURBT) surgery and reduce early recurrence rates. Funded in 2020 and launched in late 2020-early 2021, the study utilizes social media marketing and is run on a low budget. It include...
|
- Details
- Ashish Kamat converses with Alexandre Zlotta on his study comparing radical cystectomy and trimodal therapy (TMT) for muscle-invasive bladder cancer. Dr. Zlotta highlights the evolving treatment paradigm towards organ preservation with TMT, a method combining limited resection and chemoradiation. Despite the mounting evidence for TMT, it is typically reserved for patients ineligible for surgery. D...
|
